Efficacy of anti-TNF agents in PASH resolution may be related to the underlying connection between pyoderma gangrenosum (PG), hidradenitis suppurativa (HS), and inflammatory bowel disease (IBD), and can optimally be used to manage both conditions with only one medication [7, 8]. This evidence concerns the gene TNF and Pyoderma gangrenosum-acne-suppurative hidradenitis syndrome.